​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals (ALNY) stock forecast, based on 51 Wall Street analysts, predicts a 12-month average price target of $460.50, with a high of $549.00 and a low of $351.00. This represents a 43.71% increase from the last price of $320.43.

$100 $190 $280 $370 $460 $550 High: $549 Avg: $460.5 Low: $351 Last Closed Price: $320.43

ALNY Stock Rating

Alnylam Pharmaceuticals stock's rating consensus is Buy, based on 51 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 39 Buy (76.47%), 11 Hold (21.57%), 1 Sell (1.96%), and 0 Strong Sell (0.00%).

Buy
Total 51 1 11 39 Strong Sell Sell Hold Buy Strong Buy

ALNY Price Target Upside V Benchmarks

TypeNameUpside
StockAlnylam Pharmaceuticals43.71%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts51329
Avg Price Target$421.80$448.69$459.83
Last Closing Price$320.43$320.43$320.43
Upside/Downside31.64%40.03%43.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 266157--28
Feb, 266148--28
Jan, 266147-128
Dec, 256147-128
Nov, 2581461130
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 17, 2026Canaccord Genuity$429.00$314.4036.45%33.88%
Feb 13, 2026Morgan Stanley$360.00$313.7514.74%12.35%
Feb 13, 2026Bernstein$451.00$312.4344.35%40.75%
Feb 13, 2026Chardan Capital$425.00$308.4837.77%32.63%
Feb 12, 2026Paul MatteisStifel Nicolaus$444.00$313.0541.83%38.56%
Jan 30, 2026H.C. Wainwright$510.00$346.7947.06%59.16%
Jan 20, 2026RBC Capital$465.00$359.0029.53%45.12%
Jan 20, 2026Wells Fargo$376.00$359.004.74%17.34%
Jan 12, 2026Needham$529.00$398.2932.82%65.09%
Jan 12, 2026Martin AusterRaymond James$472.00$398.2918.51%47.30%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 12, 2026Bank of America SecuritiesBuyBuyhold
Jan 12, 2026NeedhamBuyBuyhold
Jan 12, 2026Bank of America SecuritiesBuyBuyhold
Jan 12, 2026Raymond JamesOutperformOutperformhold
Nov 04, 2025H.C. WainwrightBuyBuyhold
Oct 31, 2025BarclaysOverweightOverweighthold
Oct 31, 2025OppenheimerOutperformOutperformhold
Oct 30, 2025Morgan StanleyOutperformOutperformhold
Oct 22, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 05, 2025BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.20$-9.30$-3.52$-2.18$2.39---
Avg Forecast$-6.44$-8.95$-3.48$-2.10$-1.04$2.91$6.52$12.25
High Forecast$-5.41$-7.68$-2.38$0.75$4.40$9.93$19.04$15.89
Low Forecast$-7.61$-10.93$-4.20$-3.77$-11.85$-1.93$2.05$10.34
Surprise %11.80%3.91%1.15%3.81%-329.81%---

Revenue Forecast

$500M $2B $3B $5B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$844.29M$1.04B$1.83B$2.25B$3.71B---
Avg Forecast$820.81M$1.01B$1.83B$2.24B$2.65B$3.54B$4.54B$5.85B
High Forecast$934.80M$1.19B$1.88B$2.27B$3.06B$3.55B$4.61B$7.19B
Low Forecast$719.95M$902.76M$1.77B$2.20B$2.40B$3.53B$4.47B$5.15B
Surprise %2.86%2.38%0.12%0.35%40.28%---

Net Income Forecast

$-2B $-700M $100M $900M $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-852.82M$-1.13B$-440.24M$-278.16M$313.75M---
Avg Forecast$-723.17M$-770.44M$-440.24M$-332.26M$-196.87M$330.06M$942.06M$1.53B
High Forecast$-578.53M$-616.35M$-352.19M$94.21M$549.62M$1.24B$2.38B$1.99B
Low Forecast$-867.80M$-924.53M$-528.29M$-471.06M$-1.48B$-240.59M$255.91M$1.29B
Surprise %17.93%46.82%--16.28%-259.37%---

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals stock a buy?

Alnylam Pharmaceuticals stock has a consensus rating of Buy, based on 51 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 39 Buy, 11 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Alnylam Pharmaceuticals is a favorable investment for most analysts.

What is Alnylam Pharmaceuticals's price target?

Alnylam Pharmaceuticals's price target, set by 51 Wall Street analysts, averages $460.5 over the next 12 months. The price target range spans from $351 at the low end to $549 at the high end, suggesting a potential 43.71% change from the previous closing price of $320.43.

How does Alnylam Pharmaceuticals stock forecast compare to its benchmarks?

Alnylam Pharmaceuticals's stock forecast shows a 43.71% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Alnylam Pharmaceuticals over the past three months?

  • March 2026: 21.43% Strong Buy, 53.57% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 21.43% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 21.43% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 3.57% Strong Sell.

What is Alnylam Pharmaceuticals’s EPS forecast?

Alnylam Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $2.91, marking a 21.76% increase from the reported $2.39 in 2025. Estimates for the following years are $6.52 in 2027, and $12.25 in 2028.

What is Alnylam Pharmaceuticals’s revenue forecast?

Alnylam Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $3.54B, reflecting a -4.60% decrease from the reported $3.71B in 2025. The forecast for 2027 is $4.54B, and $5.85B for 2028.

What is Alnylam Pharmaceuticals’s net income forecast?

Alnylam Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $330.06M, representing an 5.20% increase from the reported $313.75M in 2025. Projections indicate $942.06M in 2027, and $1.53B in 2028.